Vicore has dosed the first patient in a study assessing the effect of its angiotensin II type 2 receptor agonist (ATRAG) C21 on endothelial dysfunction in type-2-diabetes-mellitus patients.
Vicore Pharma has announced that the first patient has been dosed with its C21 candidate during a pivotal clinical study of endothelial dysfunction.
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. nVicore is conducting a randomized, double-blind, placebo-controlled, cross-over trial evaluating the effect of ATRAGs on endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus (T2DM)[1], a condition where endothelial dysfunction is central in the development of organ damage. The trial will be conducted with Vicore’s first ATRAG C21 and will use EndoPAT®[2], an FDA approved, non-invasive, simple, and robust technology to detect endothelial dysfunction. The first patient has now been dosed and results from the trial are expected in Q4, 2023. If proof-of-principle is reached, this would both strengthen the view that ATRAGs may be useful in several major common diseases, and that the EndoPAT® technique can be used for exploring therapeutic efficacy in diseases driven by endothelial dysfunction as well as for establishing the active dose-range for new ATRAGs.
Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), provides a new interim analysis of the ongoing AIR trial, a phase 2a study in idiopathic pulmonary fibrosis (IPF).
GOTHENBURG, Sweden, Oct. 6, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ('Vicore') pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive results for the pilot phase of the COMPANION study. Vicore's digital Cognitive Behavioral Therapy (CBT), AlmeeTM; for patients with pulmonary fibrosis was safe, functional, user-friendly and reduced anxiety symptoms by 49% in patients with idiopathic pulmonary fibrosis (IPF).
Vicore Pharma Holding AB (publ) (Vicore), a clinical-stage pharmaceutical company, announces the first patient enrolled in the pilot phase of COMPANION, a clinical study of a digital cognitive behavioural therapy for patients with idiopathic pulmonary fibrosis (IPF).